| Code | CSB-RA006240MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to NI-0801, targeting CXCL10 (C-X-C motif chemokine ligand 10), also known as interferon gamma-induced protein 10 (IP-10). CXCL10 is a pro-inflammatory chemokine that plays a critical role in immune cell recruitment and activation by binding to the CXCR3 receptor on T cells, NK cells, and other leukocytes. This chemokine is implicated in various inflammatory and autoimmune conditions, including rheumatoid arthritis, inflammatory bowel disease, type 1 diabetes, and allograft rejection. Elevated CXCL10 levels are also associated with viral infections and certain malignancies, where it contributes to both anti-tumor immunity and tumor microenvironment modulation.
NI-0801, the reference antibody, was developed to neutralize CXCL10 activity and has been investigated in clinical trials for ulcerative colitis and other inflammatory disorders. This biosimilar provides researchers with a valuable tool for studying CXCL10-mediated immune responses, investigating chemokine signaling pathways, and exploring therapeutic strategies targeting inflammatory cascades in preclinical disease models.
There are currently no reviews for this product.